GTBP Insider Trading Activity and SEC Form 4 Filings
GTBP insider trading summary
No open-market insider purchases or sales of GT Biopharma, Inc. (GTBP) have been reported on SEC Form 4 in the past 12 months.
Latest GTBP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 11, 2023 | Michael Martin Breen | Executive Chairman/Interim CEO | Buy | $25K (50,000 @ $0.50) |
| Apr 6, 2023 | Manu Ohri | CFO & Secretary | Buy | $25K (50,000 @ $0.50) |
| Dec 22, 2020 | Bruce Wendel | Insider | Buy | $4K (441 @ $8.73) |
| Dec 22, 2020 | Steven W Weldon | Insider | Sell | $19K (47,978 @ $0.40) |
| Dec 22, 2020 | Bruce Wendel | Insider | Buy | $12K (1,374 @ $8.87) |
| Dec 21, 2020 | Steven W Weldon | Insider | Sell | $15K (50,000 @ $0.30) |
| Dec 21, 2020 | Steven W Weldon | Insider | Sell | $12K (35,722 @ $0.34) |
| Dec 21, 2020 | Steven W Weldon | Insider | Sell | $17K (50,000 @ $0.33) |
| Dec 18, 2020 | Steven W Weldon | Insider | Sell | $15K (50,000 @ $0.30) |
| Dec 17, 2020 | Steven W Weldon | Insider | Sell | $16K (50,000 @ $0.31) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.